TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Innovative Central Line Securement Device in the Pediatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a central line ages 0-18 years old who have never worn a wearable central line securement device (vest) will be eligible for the study.~Exclusion Criteria:~* Those children who currently wear a central line securement device (vest)~* Children with central lines who are 19 years or older~* Those females with central lines and Tanner 2 breast or greater breast development as a wearable central line securement device (vest) will not fit properly to secure the central line and may increase the risk of the central line complications.~* If the patient does develop breast during the time of the study then the patient will no longer wear the wrap and will go back to securing their device in the traditional way. The investgators will still collect data on that patient and they will be evaluated in the device arm consistent with the intention to treat principle.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Device (Type: EXPERIMENTAL): Those in the device arm will be given two wearable central line securement devices and the investigators will encourage continuous wear throughout the duration of the study.
- Traditional Securement Dressing (Type: ACTIVE_COMPARATOR): Those is the non-device arm will continue to wear a traditional central line securement dressing as is the standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. histologically confirmed hepatocellular carcinoma (HCC) or clinical diagnosis of HCC according to American association for the study of liver diseases （AASLD）-guidelines or clinical diagnosis criteria based on Alpha Fetoprotein （AFP), and radiological images proposed by Liver Cancer Society, Chinese Anti-Cancer Association;~2. no clinically distant metastasis;~3. Child Push score A,technically unresectable, or medically inoperable; maximal tumor size is less than 12 cm;~4. age ≥ 18 and \<80 years of age;~5. Karnofsky Performance Score ≥ 70;~6. No previous invasive cancer (within 5 years before the HCC diagnosis)except for skin non-melanoma cancer or non muscle invasive bladder cancer; Ability to understand character and individual consequences of the clinical trial;~7. Willing to sign the written informed consent; Informed consent must be signed before the enrollment in the trial;~Exclusion Criteria:~1. Distant metastasis (M1);~2. maximal tumor size is more than 12 cm;~3. tumor invading adjacent gastrointestine (T4);~4. Child push score B or C;~5. Previous hepatic radiotherapy;~6. Severe systemic disorders;~7. Previous malignancy (within 5 years) except for skin non-melanoma cancer or 3-year disease free interval from previous malignancy like in situ cervix cancer or non muscle invasive bladder cancer;~8. Non conformity of the radiotherapy dose distribution when compared to the dose constraints;~9. Psychiatric disorders or any other condition that can make unreliable the informed consent;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- carbon-ion radiotherapy for tumor away from GI (Type: EXPERIMENTAL): For tumor location which is away from gastrointestine (the distance is more than 1 cm). We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma. Four dose levels \[55 Gray equivalent (GyE)/10 fractions (Fx), 60GyE/10Fx, 65GyE/10Fx, 70GyE/10Fx\] are planned within the Phase I part.
- carbon-ion radiotherapy for tumor adjacent to GI (Type: EXPERIMENTAL): For tumor location which is adjacent to gastrointestine (less than 1 cm).We use carbon-ion radiotherapy for the treatment of hepatocellular carcinoma.~Three dose levels (carbon 60GyE/15Fx, carbon 67.5GyE/15Fx, carbon 75GyE/15Fx) are planned within the Phase I part.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Metal on Metal Versus Metal on Highly Crossed Linked Polyethylene Sytem

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female subjects 65 years of age or older~* Subjects undergoing cementless hip arthroplasty. If a press fit metal articulation acetabulum is not possible; the modular cup system will be utilized with screw fixation and a metal head of the greatest diameter deemed appropriate and safe for the patient will be utilized.(At the discretion of the surgeon). The cup in this situation may have a metal or poly articulation. The patient will be followed as an intent to treat (the patient will be evaluated and included in the group as randomized)~* Subjects with, but not limited to, original diagnoses of osteoarthritis, avascular necrosis, rheumatoid arthritis, congenital dysplasia of the hip, ankylosing spondylitis, posttraumatic arthritis, and traumatic injury to the hip joint.~* Subjects who are able and willing to understand the conditions of informed consent, to participate in the study according to the protocol for the length of the expected term of follow-up, and to follow their physician's directions.~Exclusion Criteria:~* Subjects undergoing hip arthroplasty using a cemented femoral component and/or a bipolar prosthesis.~* Subjects with gross obesity, \>45% over ideal body weight for age and height. Refer to Appendix A, Obesity Table.~* Subjects with active infections.~* Subjects with malignancy in the area of the involved hip joint.~* Subjects with a neuromuscular deficit that interferes with the subject's ability to limit weight bearing or places an extreme load on the implant during the healing period.~* Subjects with a diagnosis of Fibromyalgia~* Female subjects who are pregnant or may be pregnant.~* Subjects whom, as judged by the surgeon, are not capable of understanding the informed consent or the requirements of the protocol, or are reasonably unlikely to be compliant with the prescribed postoperative routine and the follow-up evaluation schedule.~* Subjects who have a known sensitivity to device materials.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metal on Metal (Type: ACTIVE_COMPARATOR): Metal on Metal articulation system
- HCLPC (Type: ACTIVE_COMPARATOR): THA using Highly Cross Linked Polyethylene cup System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Glucocorticoid Treatment for Social Phobia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age (20-55)~* Spider Phobia~* Right Handed~* Social Phobia~Exclusion Criteria:~* Other Psychiatric Disorder / Comorbidities~* Smoking more than 15 cigarettes per day~* Medication~* Contraceptives~* Physical illness~* Neurological disease~* Drug abuse

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1: CBGT & Hydrocortisone (Type: ACTIVE_COMPARATOR): None
- 2: CBGT & Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male~* Age: ≥18 years old~* Patients with primary open angle glaucoma with mild to moderate damage or ocular hypertension that were sufficiently controlled with GAAP Ofteno® (latanoprost 0.005%) within the last 60 days~* Signed Informed Consent Form~Exclusion Criteria:~* Subjects with unique eye~* Subjects with visual acuity \< 20/200~* Another kind of glaucoma disease different to primary open angle glaucoma~* corneal disturbances with impossibility to measure the intraocular pressure~* retinal alterations without control or progressive retinal disease with high risk to lost vision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (PRO-067) (Type: EXPERIMENTAL): study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours
- Sequence 2 (GAAP Ofteno®) (Type: ACTIVE_COMPARATOR): study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of hormone receptor (HR)-negative, human epidermal growth factor receptor 2 (HER2)-negative (locally recurrent or metastatic TNBC) breast cancer~* Available TNBC diagnostic tumor tissue (archived tissue allowed)~* Evaluable disease~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1~* Adequate organ function~* Predicted life expectancy of 3 or more months~Exclusion Criteria:~* More than 2 prior chemotherapy regimens for locally recurrent or metastatic TNBC. If \> 12 months have elapsed between the date of last adjuvant/neoadjuvant chemotherapy administration and first documented local or distant disease recurrence the therapy will not be considered a line of therapy in the locally recurrent or metastatic TNBC setting.~* CNS metastases or leptomeningeal disease requiring immediate treatment with radiation therapy or steroids.~* Investigational drug within 30 days of first trilaciclib (G1T28) dose~* Concurrent radiotherapy, radiotherapy within 14 days of first trilaciclib (G1T28) dose~* Cytotoxic chemotherapy within 3 weeks of first trilaciclib (G1T28) dose~* Prior hematopoietic stem cell or bone marrow transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Gemcitabine/Carboplatin (Days 1 and 8) (Type: EXPERIMENTAL): Participants received Intravenous (IV) infusion of standard GC chemotherapy (gemcitabine 1000 milligrams per meter square \[mg/m\^2\] and carboplatin area under the curve \[AUC\] 2) on Days 1 and 8 of 21-day cycle. The carboplatin dose was calculated using the Calvert formula, with a target AUC 2 (maximum 300 mg).
- Group 2: Trilaciclib + Gemcitabine/ Carboplatin (Days 1 and 8) (Type: EXPERIMENTAL): Participants received IV infusion of trilaciclib 240 mg/m\^2 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Days 1 and 8 of 21-day cycle. Trilaciclib was administered prior to chemotherapy.
- Group 3: Trilaciclib (Days 1, 2, 8 and 9) + Gemcitabine/Carboplatin (Days 2 and 9) (Type: EXPERIMENTAL): Participants received IV infusion of trilaciclib 240 mg/m\^2 on Days 1, 2, 8, and 9 plus GC chemotherapy (gemcitabine 1000 mg/m\^2 and carboplatin AUC 2) IV infusion on Day 2 and 9 of 21-day Cycle. Trilaciclib was administered prior to chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18~* performance of a SARS-CoV-2 test within 1 day of enrollment, N.B., must be positive to proceed to treatment phase of the trial~Exclusion Criteria:~* All patients under 18~* Known allergy to N-Acetyl Cysteine~* Known allergy to famotidine or other H2-receptor antagonists~* Pregnant or Nursing Mothers~* Laboratory Evidence or History of Renal Impairment (eGFR \< 30 mL/min/1.73 m2)~* Taking H2-receptor antagonists, hydroxychloroquine or chloroquine.~* Patient has been admitted to the hospital prior to study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose N-Acetyl Cysteine Alone (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily
- Medium Dose N-Acetyl Cysteine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily
- Low Dose N-Acetyl Cysteine and Low Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
- High Dose N-Acetyl Cysteine Alone (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily
- Medium Dose N-Acetyl Cysteine and Low Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
- Low Dose N-Acetyl Cysteine and Medium Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
- High Dose N-Acetyl Cysteine and Low Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
- Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
- Low Dose N-Acetyl Cysteine and High Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
- High Dose N-Acetyl Cysteine and Medium Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
- Medium Dose N-Acetyl Cysteine and High Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
- High Dose N-Acetyl Cysteine and High Dose Famotidine (Type: EXPERIMENTAL): N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* must have metastatic breast cancer~* must have cytologically or pathologically confirmed invasive ductal or lobular carcinoma~* must have measurable or evaluable disease~* ECOG of 0-1~* patients may have received 0, 1. or 2 prior treatments for metastatic breast cancer~* must have adequate organ function~* must be at least 19 years of age~* peripheral neuropathy less than or equal to grade 1~* must have voluntarily signed informed consent~* patients with brain metastases are eligible provided that other measurable disease exists and brain lesions are controlled~Exclusion Criteria:~* patients with other malignancies, except non melanoma of the skin, who have had any evidence of cancer within the last 5 years~* patients with psychiatric illness or other concurrent severe co-morbid medical condition that would preclude study completion~* known uncontrolled existing coagulopathy~* patients with a history of severe hypersensitivity reaction to docetaxel, medications formulated with polysorbate 80 or 5-fluorouracil~* use of other investigational agents in the last 28 days~* pregnant or lactating women~* patients who are known HIV positive~* patients with life expectancy of less than 3 months~* sexually active patients unwilling to practice reliable contraception during the study

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Medical Treatment in MS Patients Suffering From Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* multiple sclerosis~* fatigue~* MFIS values greater than 34 or Pittsburgh Sleep Quality Index greater than 5~Exclusion Criteria:~* Expanded disability status scale greater than 5~* relapse in the last four weeks~* immunosuppressants in the last two years~* therapy with positive airway pressure (CPAP or BIPAP/ASV)~* treatment with opioids~* treatment with oestrogen~* body mass index greater than 40~* depression (beck depression inventory (BDI) values greater 20; in case of treatment with antidepressants BDI values greater than 12 or suicidal ideas)~* pregnancy~* anaemia (hemoglobine \< 11,5 g/dl in women and \< 12,5 g/dl in men)~* thyroid-stimulating hormone outside the normal range~* renal insufficiency (creatinine clearance \< 75ml/min)~* elevated transaminases (tripled)~* chronic heart failure (NYHA II, III or IV)~* respiratory insufficiency (CO2 \> 45 mmHg or pO2 \< 60 mmHg (capillary or arterial) or long-term oxygen therapy)~* carcinoma in the medical history (except for curative approach without relapse in the last 10 years)~* chemotherapy~* poorly controlled diabetes (Glycated hemoglobin greater than 8 per cent)~* pituitary adenomas~* diabetes insipidus~* fibromyalgia~* unclear weight loss greater than 12 kg in one year~* myasthenia gravis or any neuromuscular disorder~* ulcerating colitis or Crohn's disease~* AIDS or infection with HIV~* acute infection in the last two months~* stroke or apoplexy in the history~* Parkinson's Disease~* substance or drug abuse~* participation in other interventional trials~* capacity for consent is lacking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Standard Treatment of Sleep disorder according to applicable guideline
- Waiting list (Type: NO_INTERVENTION): Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Automated Insulin Pump Settings Using the Advisor Pro (Previously Called) MD-Logic Pump Advisor-three Segments Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented Type 1 Diabetes for at least 1 year prior to study enrollment~* Segment A:Subjects aged ≥ 10 years and up to 25 years Segment B: Subjects aged ≥ 6 years Segment C: Subjects aged ≥ 6 years and up to 30 years~* HbA1c at inclusion ≤ 11%~* Insulin pump therapy for at least 4 months for segment A and C and at least 3 months for segment B~* BMI Standard Deviation Score - below the 97th percentile for age~* Subjects have continuous glucose monitoring data for at least 2-3 weeks before the clinic regular visit (for segment B only)~* Without routine sensor use (for segment C only)~* Subjects willing to follow study instructions~Exclusion Criteria:~* An episode of diabetic keto-acidosis within the month prior to study entry~* Severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrollment~* Concomitant diseases/ treatment that influence metabolic control~* Significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subjects ability to complete the study or compromise patients safety~* Participation in any other interventional study~* Known or suspected allergy to trial products~* Female subject who is pregnant or planning to become pregnant within the planned study duration.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- MD Logic Pump Advisor (Type: EXPERIMENTAL): Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
- Control Group-Medical guided recommendations (Type: ACTIVE_COMPARATOR): Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility